Garry Kann - Endonovo Therapeutics Head Devel

ENDV Stock

USD 0.0006 0.0001 14.29%

Insider

Garry Kann is Head Devel of Endonovo Therapeutics

Phone	800 489 4774
Web	https://www.endonovo.com

Endonovo Therapeutics Management Efficiency

The company has return on total asset (ROA) of (1.0992) % which means that it has lost $1.0992 on every $100 spent on assets. This is way below average. Endonovo Therapeutics' management efficiency ratios could be used to measure how well Endonovo Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Compare Endonovo Therapeutics to Peers

Predict price of Endonovo Therapeutics

Endonovo Therapeutics currently holds 7.36 M in liabilities. Debt can assist Endonovo Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Endonovo Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Endonovo Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Endonovo to invest in growth at high rates of return. When we think about Endonovo Therapeutics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives			INSIDER Age
	Anish MD	Soleno Therapeutics	54
	Tiago Marques	Pasithea Therapeutics Corp	47
	Dr MBA	MediciNova	59
	Kyung NamWortman	Cellectis SA	53
	Fabien Sebille	Purple Biotech	50
	Ming Yin	Bolt Biotherapeutics	N/A
	MBA CFA	Bolt Biotherapeutics	60
	Steven King	Mosaic Immunoengineering	59
	Edgar MD	Bolt Biotherapeutics	78
	Joseph MPH	Mosaic Immunoengineering	50
	Nir Livneh	Purple Biotech	45
	Karen Bergman	Bolt Biotherapeutics	N/A
	Jean Epinat	Cellectis SA	N/A
	Randall Schatzman	Bolt Biotherapeutics	69
	Greg Leszczynski	Covalon Technologies	N/A
	Elaine Zhang	Covalon Technologies	N/A
	Jason Gorel	Covalon Technologies	N/A
	Paul CPA	Mosaic Immunoengineering	55
	Gerry Arambula	Covalon Technologies	N/A
	Daniel Schneiderman	Pasithea Therapeutics Corp	46
	John CPA	MediciNova	N/A

Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California. Endonovo Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. Endonovo Therapeutics [ENDV] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC).

Management Performance

Return On Asset

-1.1

Endonovo Therapeutics Leadership Team

Elected by the shareholders, the Endonovo Therapeutics' board of directors comprises two types of representatives: Endonovo Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Endonovo. The board's role is to monitor Endonovo Therapeutics' management team and ensure that shareholders' interests are well served. Endonovo Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Endonovo Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.

	Ira Weisberg, Pres Division
	Alan Collier, Chairman, CEO, Principal Accounting Officer, Interim CFO and Secretary
	Don Calabria, VP Operations
	Garry Kann, Head Devel

Endonovo Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Endonovo Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Asset	-1.1
	Operating Margin	(222.06) %
	Current Valuation	9.74 M
	Shares Outstanding	194.33 M
	Shares Owned By Insiders	24.61 %
	Price To Earning	(1.04) X
	Price To Sales	202.42 X
	Revenue	73.11 K
	Gross Profit	58.12 K
	EBITDA	(1.51 M)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Endonovo Pink Sheet Analysis

When running Endonovo Therapeutics' price analysis, check to measure Endonovo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Endonovo Therapeutics is operating at the current time. Most of Endonovo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Endonovo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Endonovo Therapeutics' price. Additionally, you may evaluate how the addition of Endonovo Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC